Publication | Open Access

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

Hematological MalignancyMedicineImmune Checkpoint InhibitorMultiple MyelomaPharmacotherapyCancer TreatmentOncologyRadiation OncologyPhase 1Refractory Lymphoma